Oxalosis Agent - Oxalate Inhibitor

"Oxalosis Agent - Oxalate Inhibitor" is a formulary and compendial classification rather than a formal FDA Established Pharmacologic Class, primarily encompassing targeted small interfering RNA (siRNA) therapies such as lumasiran and nedosiran.

These therapeutic agents work by silencing specific hepatic enzymes—such as glycolate oxidase or hepatic lactate dehydrogenase—thereby reducing endogenous synthesis of oxalate in the liver.

Their principal clinical role is to treat primary hyperoxaluria, an ultra-rare metabolic disorder characterized by systemic oxalosis, recurrent nephrolithiasis, and progressive renal impairment.